Document Detail


An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection.
MedLine Citation:
PMID:  15249178     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Erythropoietin (Epo) was once thought to act exclusively in the formation of red blood cells. As recently reviewed by Smith et al. [Cardiovasc. Res. 59 (2003) 538-548], Epo can also act within the cardiovascular system with effects in thrombosis and hypertension as well as actions on platelets, vascular endothelium and smooth muscle, and myocytes of the heart. Here, the actions of Epo to protect neuronal cells of the brain are first evaluated and parallel actions of Epo in cardioprotection are then drawn. Thus, with recent reports of Epo receptor (EpoR) expression by cardiac myocytes, it could be predicted that Epo initiates direct protective signalling events. This is supported by five independent studies published in 2003 showing Epo protects cardiac myocytes following ischemia/reperfusion. Importantly, these protective actions have been observed in vitro and in vivo. The former suggests the direct actions of Epo to prevent myocyte death independently of its effects on red blood cell number or cells other than cardiac myocytes. The latter demonstrates the potential for Epo in the treatment of the heart post-infarction, decreasing the numbers of apoptotic myocytes, limiting infarct expansion and attenuating the post-infarct deterioration in haemodynamic function. These beneficial effects of Epo should stimulate further research into the actions of Epo.
Authors:
Marie A Bogoyevitch
Related Documents :
15524178 - Human vegf165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative...
6465048 - The transverse-axial tubular system (tats) of mouse myocardium: its morphology in the d...
17570028 - A 3-d model of coronary vessel development.
17605008 - The similar effect of transplantation of marrow-derived mesenchymal stem cells with or ...
15497388 - Blood damage related to cardiopulmonary bypass: in vivo and in vitro comparison of two ...
9420758 - The value of perioperative clinical indexes and dipyridamole thallium scintigraphy for ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular research     Volume:  63     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-07-13     Completed Date:  2004-10-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  208-16     Citation Subset:  IM    
Copyright Information:
Copyright 2004 European Society of Cardiology
Affiliation:
Cell Signalling Laboratory, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, University of Western Australia, Australia. marieb@cyllene.uwa.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apoptosis
Erythropoietin / physiology*
Humans
Myocardial Reperfusion Injury / metabolism*,  pathology
Myocardium / metabolism*
Myocytes, Cardiac / metabolism*,  pathology
Necrosis
Neurons / metabolism*
Chemical
Reg. No./Substance:
11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  GATA transcription factors in the developing and adult heart.
Next Document:  Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin I...